Expression of long-chain fatty Acyl-CoA synthetase 4 in breast and prostate cancers is associated with sex steroid hormone receptor negativity

Translational Oncology

Volumn 3, Issue 2, 2010, Pages 91-98

  Monaco, Marie E ^a,b   Creighton, Chad J ^c,d   Lee, Peng ^a,b   Zou, Xuanyi ^b   Topham, Matthew K ^e,f   Stafforini, Diana M ^e,f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Dan L Duncan Cancer Center   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; LONG CHAIN FATTY ACID COENZYME A LIGASE; LONG CHAIN FATTY ACID COENZYME A LIGASE 4; MESSENGER RNA; RAF PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 77953445730     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09202     Document Type: Article

References (57)

1. Menendez JA and Lupu R (2007). Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7 (10), 763-777.
2. Brunet J, Vazquez-Martin A, Colomer R, Graña-Suarez B, Martin-Castillo B, and Menendez JA (2008). BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer. Mol Carcinog 47 (2), 157-163.
3. Black PN, Fargeman NJ, and DiRusso CC (2000). Long-chain acyl-CoA-dependent regulation of gene expression in bacteria, yeast and mammals. J Nutr 130 (2), 305s-309s.
4. Coleman RA and Lee DP (2004). Enzymes of triacylglycerol synthesis and their regulation. Prog Lipid Res 43, 134-176.
5. Cao Y, Traer E, Zimmerman GA, McIntyre TM, and Prescott SM (1998). Cloning, expression, and chromosomal localization of human long-chain fatty acid-CoA ligase 4 (FACL4). Genomics 49, 327-330.
6. Cao Y, Dave KB, Doan TP, and Prescott SM (2001). Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma. Cancer Res 61, 8429-8434.
7. Sung YKP, Park MK, Hong SY, Hwang SY, Kwack MH, Kim JC, and Kim MK (2007). Regulation of cell growth by fatty acyl-CoA ligase 4 in human hepatocarcinoma cells. Exp Mol Med 39 (4), 477-482.
8. Peng Y, Chen F, Melamed J, Chiriboga L, Wei J, Kong X, McLeod M, Li Y, Li CX, Keng A, et al. (2008). Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci USA 105 (13), 5236-5241.
9. Li Y, Wang L, Zhang M, Melamed J, Liu X, Reiter R, et al. (2009). LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res 69 (8), 3332-3338.
10. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. (2004). Oncomine: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1-6.
11. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. (2005). From the cover: an expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102 (38), 13550-13555.
12. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, et al. (2006). Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66 (21), 10292-10301.
13. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil DW, et al. (2002). A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (25), 1999-2009.
14. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (9460), 671-679.
15. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature 436 (7050), 518-524.
16. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. (2006). Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (4), 262-272.
17. Yu K, Ganesan K, Miller LD, and Tan P (2006). A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors. Clin Cancer Res 12 (11), 3288-3296.
18. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo W-L, et al. (2006). Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10 (6), 529-541.
19. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She Q-B, Maurer M, et al. (2007). Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 104 (18), 7564-7569.
20. Bittner M (2005). Expression Project for Oncology (expO). National Center for Biotechnology Information. Available at: http://www.ncbi.nlm.nih.gov/geo/.
21. Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adelaide J, et al. (2006). Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res 12 (15), 4533-4544.
22. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, et al. (2006). Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24 (26), 4236-4244.
23. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10 (6), 515-527.
24. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al. (2005). Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24 (29), 4660-4671.
25. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, et al. (2006). An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25 (28), 3994-4008.
26. Zhao H, Kim Y, Wang P, Lapointe J, Tibshirani R, Pollack JR, et al. (2005). Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate 63 (2), 187-197.
27. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, et al. (2004). Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164 (1), 217-227.
28. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, and El-Ashry D (2006). Activation of mitogen-activated protein kinase in estrogen receptor {alpha}-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor {alpha}-negative human breast tumors. Cancer Res 66 (7), 3903-3911.
29. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, and El-Ashry D (2001). Hyperactivation of MAPK induces loss of ER{alpha} expression in breast cancer cells. Mol Endocrinol 15 (8), 1344-1359.
30. Van Horn CG, Caviglia JM, Li LO, Wang S, Granger DA, and Coleman RA (2005). Characterization of recombinant long-chain rat acyl-CoA synthetase isoforms 3 and 6: identification of a novel variant of isoform 6. Biochemistry 44 (5), 1635-1642.
31. Mashima T, Sato S, Okabe S, Miyata S, Matsuura M, Sugimoto Y, et al. (2009). Acyl-CoA synthetase as a cancer survival factor: its inhibition enhances the efficacy of etoposide. Cancer Sci 100, 1556-1562.
32. Kuhajda FP (2006). Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66 (12), 5977-5980.
33. Swinnen JVB, Brusselmans K, and Verhoeven G (2006). Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 9, 358-365.
34. Milgraum LZ, Witters LA, Pasternack GR, and Kuhajda FP (1997). Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 3 (11), 2115-2120.
35. Chajes V, Cambot M, Moreau K, Lenoir GM, and Joulin V (2006). Acetyl-CoA carboxylase {alpha} is essential to breast cancer cell survival. Cancer Res 66 (10), 5287-5294.
36. Alli PM, Pinn ML, Jaffee EM, McFadden JM, and Kuhajda FP (2004). Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 24 (1), 39-46.
37. Lupu R and Menendez JA (2006). Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators? Endocrinology 147 (9), 4056-4066.
38. Menendez JV, Vellon L, Colomer R, and Lupu R (2005). Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int J Cancer 115 (1), 19-35.
39. Liu Y (2006). Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 9 (3), 230-234.
40. Vazquez-Martin A, Colomer R, Brunet J, Lupu R, and Menendez JA (2008). Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif 41 (1), 59-85.
41. Li LO, Mashek DG, An J, Doughman SD, Newgard CB, and Coleman RA (2006). Overexpression of rat long chain acyl-CoA synthetase 1 alters fatty acid metabolism in rat primary hepatocytes. J Biol Chem 281 (48), 37246-37255.
42. Parkes HA, Preston E, Wilks D, Ballesteros M, Carpenter L, Wood L, et al. (2006). Overexpression of acyl-CoA synthetase-1 increases lipid deposition in hepatic (HepG2) cells and rodent liver in vivo. Am J Physiol Endocrinol Metab 291 (4), E737-E744.
43. Zhou Y, Abidi P, Kim A, Chen W, Huang T-T, Kraemer FB, et al. (2007). Transcriptional activation of hepatic ACSL3 and ACSL5 by oncostatin M reduces hypertriglyceridemia through enhanced {beta}-oxidation. Arterioscler Thromb Vasc Biol 27 (10), 2198-2205.
44. Lewin TMVH, Van Horn CG, Krisans SK, and Coleman RA (2002). Rat liver acyl-CoA synthetase 4 is a peripheral-membrane protein located in two distinct subcellular organelles, peroxisomes, and mitochondrial-associated membrane. Arch Biochem Biophys 404, 263-270.
45. Kim J-H, Lewin TM, and Coleman RA (2001). Expression and characterization of recombinant rat acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones. J Biol Chem 276 (27), 24667-24673.
46. Piccini M, Vitelli F, Bruttini M, Pober BR, Jonsson JJ, Villanova M, et al. (1998). FACL4, a new gene encoding long-chain acyl-CoA synthetase 4, is deleted in a family with Alport syndrome, elliptocytosis, and mental retardation. Genomics 47, 350-358.
47. Meloni I, Muscettola M, Raynaud M, Longo I, Bruttini M, Moizard MP, et al. (2002). FACL4, encoding fatty acid-CoA ligase 4, is mutated in non-specific X-linked mental retardation. Nat Genet 30, 436-440.
48. Cho YY, Kang MJ, Sone H, Suzuki T, Abe M, Igarashi M, et al. (2001). Abnormal uterus with polycysts, accumulation of uterine prostaglandins, and reduced fertility in mice heterozygous for acyl-CoA synthetase 4 deficiency. Biochem Biophys Res Commun 284, 993-997.
49. Liang YC, Wu CH, Chu JS, Wang CK, Hung LF, Wang YJ, et al. (2005). Involvement of fatty acid-CoA ligase 4 in hepatocellular carcinoma growth: roles of cyclic AMP and p38 mitogen-activated protein kinase. World J Gastroenterol 11, 2557-2563.
50. Sung KY, Hwang SY, Park MK, Bae HI, Kim WH, Kim JC, et al. (2003). Fatty acid-CoA ligase 4 is overexpressed in human hepatocellular carcinoma. Cancer Sci 94, 421-424.
51. Mashek DGL, Li LO, and Coleman RA (2006). Rat long-chain acyl-CoA synthetase mRNA, protein, and activity vary in tissue distribution and response to diet. J Lipid Res 47, 2004-2010.
52. Lu S, Tsai SY, and Tsai M-J (1999). Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology 140 (11), 5054-5059.
53. Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, Flohr P, et al. (2008). Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer 99, 314-320.
54. Yu JY, Yu J, Cordero KE, Johnson MD, Ghosh D, Rae JM, Chinnaiyan AM, and Lippman ME (2008). A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. Neoplasia 10 (1), 79-88.
55. Kasper S and Cookson MS (2006). Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 33 (2), 201-210.
56. Hendriksen PJM, Dits NFJ, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, et al. (2006). Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 66 (10), 5012-5020.
57. Mashima T, Sato S, Sugimoto Y, Tsuruo T, and Seimiya H (2008). Promotion of glioma cell survival by acyl-CoA synthetase 5 under extracellular acidosis conditions. Oncogene 28, 9-19.